Boehringer Ingelheim Enters into a Clinical Collaboration with Amgen to Evaluate BI 1701963 + Lumakras (sotorasib) for Locally Advanced or Metastatic NSCLC

 Boehringer Ingelheim Enters into a Clinical Collaboration with Amgen to Evaluate BI 1701963 + Lumakras (sotorasib) for Locally Advanced or Metastatic NSCLC

Shots:

  • The companies collaborated to evaluate the synergistic effects of BI 1701963 (SOS1::pan-KRAS inhibitor) + Lumakras (KRAS G12C inhibitor) in a P-I trial for adult patients with LA or metastatic NSCLC
  • The companies will jointly share costs & manage the clinical development for combined therapy. Amgen will sponsor the trial
  • The preclinical data showed that the combination may result in increased anti-tumor activity based on complementary mechanisms of targeted oncology agents. BI 1701963 is currently being evaluated in P-I trials as monothx. and in combination with MEK inhibitors, KRASG12C inhibitors, or irinotecan for the treatment of advanced KRAS-mutated cancers

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Longevity Technology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post